2018;16:e2006203
Cagrilintide offers a focused, amylin-based strategy with milder side effects and strong combination therapy potential
Injection volume is typically 0.5-1 mL administered intramuscularly or subcutaneously weekly
17 , 254264 (2010) Gavrish, E
It is the natural next read for anyone who suspects copper peptides are not their match
261, 262 Although high rates of efficacy were reported (47 to 64%), given the extremely small combined sample size of fewer than 30 patients, the relatively serious AEs (e.g., new diabetes onset, exacerbation of existing diabetes, pneumonia with septic shock, increased blood pressure), and the known risks of systemic long-term glucorticoid use, risks/burdens clearly outweigh benefits and the Panel recommends that this therapy not be used long-term